The USPTO has granted a patent to Vistagen’s non-opioid oral product candidate AV-101 for neuropathic pain treatment.

An increase in high-fat, high-fructose foods in people's diets has contributed to a dramatic increase in type 2 diabetes.

Algiax Pharmaceuticals, a company committed to developing innovative treatments for chronic neuropathic pain, has released ...

Objective: To assess the efficacy, safety and impact on quality of life of tramadol in the treatment of neuropathic pain in patients with cancer. Methods: Patients with similar characteristics ...

for the treatment of neuropathic pain. The patent will not expire until at least 2034 and is part of Vistagen’s global patent portfolio on manufacturing methods and therapeutic uses for AV-101 ...

The manufacturer of AV-101, an investigational, oral nonopioid, NMDA-targeting therapy to treat neuropathic pain, announced ...

Nerve Renew is a dietary supplement designed to address neurological problems and restore healthy nerve function. The formula ...

Acupuncture is proving effective for chronic sciatica relief A new clinical trial reveals its potential to reduce pain and ...

The U.S. FDA has granted Fast Track designation for development of AV-101 as a potential non-opioid treatment for neuropathic pain and adjunctive treatment of major depressive disorder.

Vistagen (VTGN) announced that the U.S. Patent and Trademark Office or USPTO, granted a patent to the company for its oral non-opioid product ...